A5102977378- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Cytokine Signaling Pathways and Interactions
- Advanced Radiotherapy Techniques
- Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
- Colorectal and Anal Carcinomas
- Glioma Diagnosis and Treatment
- RNA modifications and cancer
- Head and Neck Cancer Studies
- Glycosylation and Glycoproteins Research
Lishui City People's Hospital
2023-2024
Merck & Co., Inc., Rahway, NJ, USA (United States)
2019-2023
Wenzhou Medical University
2023
Istituto Oncologico Veneto
2018
Bristol-Myers Squibb (United States)
2017-2018
Novartis (United States)
2013-2017
Novartis (Switzerland)
2015
Foundation for Biomedical Research
2014
Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the cohort of CheckMate-142, largest single-study report an immunotherapy combination...
5504 Background: Treatment options for cervical, vaginal, and vulvar (GYN) cancers are limited after first-line therapy. Human papillomavirus (HPV) infection is associated with squamous cell carcinomas of the cervix (≥90%) vulva/vagina (40–70%), may elicit an immune reaction. Programmed death (PD)-1 its major ligand PD-L1 expressed in GYN inhibit responses. Nivolumab disrupts PD-1–mediated signaling, restoring antitumor immunity. Methods: In CheckMate 358 (NCT02488759), ongoing multicohort...
Abstract Purpose: This prespecified exploratory analysis evaluated the association between tumor mutational burden (TMB) status and outcomes of first-line pembrolizumab±chemotherapy versus chemotherapy in KEYNOTE-062. Patients Methods: In patients with advanced gastric cancer evaluable TMB data, we (continuous variable; square root scale) assessed FoundationOne CDx clinical [objective response rate (ORR), progression-free survival (PFS), overall (OS)] using logistic (ORR) Cox proportional...
In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including relationship CPS microsatellite instability-high (MSI-H) status.In patients whole exome...
519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch repair (dMMR) system. dMMR/MSI-H CRC exhibits an increased tumor neoantigen load and immune cell infiltration is hypothesized to be targetable by checkpoint inhibitors. CheckMate 142 (NCT02060188) evaluates the efficacy safety nivolumab (nivo) in patients (pts) mCRC. Methods: Pts mCRC who progressed on/were intolerant ≥1...
553 Background: Nivolumab (NIVO) provided durable responses (investigator-assessed [INV] ORR, 31%) and disease control (DCR, 69%) in pretreated pts with dMMR/MSI-H mCRC CheckMate-142 (NCT02060188; Overman et al Lancet Oncol 2017). An interim analysis of the NIVO + ipilimumab (IPI) combination cohort reported a preliminary ORR 55% manageable safety profile subset (n = 84) ≥ 6 mo follow-up (André ASCO Here we report for first time efficacy from complete population (N 119) IPI CheckMate-142,...
Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval initial control. Improved response rates have been demonstrated the addition ICIs cytotoxic therapies, leading approvals from US Food and Drug Administration regulatory agencies in other countries ICI−chemotherapy combinations...
4537 Background: KEYNOTE-061 (NCT02370498) was a randomized, open-label, phase 3 study of pembrolizumab vs paclitaxel in pts with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma tumor progression after first-line therapy (N = 592). In this analysis, we evaluated tTMB using FoundationOne CDx (F1CDx; Foundation Medicine) GEJ cancer KEYNOTE-061. Methods: evaluable F1CDx data (n 204), analyzed the association confirmed objective response rate (ORR), progression-free survival...
554 Background: Nivolumab (NIVO) provided durable responses (ORR, 32% per central assessment) and disease control (DCR, 64%) in pre-treated pts with dMMR/MSI-H mCRC (NCT02060188; Overman MJ et al Lancet Oncol 2017). NIVO was approved the US for who progress after standard chemotherapy (SC) a fluoropyrimidine (F), oxaliplatin (Ox), irinotecan (Iri). Here we present long-term survival outcomes by prior CheckMate-142. Methods: Pts received 3 mg/kg Q2W. The primary endpoint ORR RECIST 1.1. Other...
Background In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gastroesophageal junction (G/GEJ) cancer but elicit a longer duration of response and offered favorable safety profile. This prespecified exploratory analysis was conducted to evaluate associations between tumor gene expression signatures clinical...
9505 Background: MCC is a rare, aggressive skin cancer commonly associated with the oncogenic Merkel cell polyomavirus (MCPyV). The PD-1/PD-L1 immunosuppressive pathway often upregulated in MCC, and advanced metastatic responsive to PD-1 blockade. Here we report first trial of anti–PD-1 neoadjuvant setting for resectable MCC. Methods: In phase 1/2 CheckMate 358 nivo virus-associated cancers (NCT02488759), patients (pts) received 240 mg IV on D1 D15. Surgery was planned D29. Tumor regression...
4512 Background: KEYNOTE-061 (NCT02370498) was a randomized, open-label, phase 3 study of pembrolizumab vs paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma tumor progression after first-line therapy (N =592). We explored the association tissue mutational burden (tTMB) status and clinical outcomes GC enrolled KEYNOTE-061, including relationship PD-L1 combined positive score (CPS) microsatellite instability-high (MSI-H) status. Methods: In from evaluable...
Preoperative stratification is critical for the management of patients with esophageal cancer (EC). To investigate feasibility and accuracy PET-CT-based radiomics in preoperative prediction clinical pathological stages EC.Histologically confirmed 100 EC PET-CT images were enrolled retrospectively randomly divided into training validation cohorts at a ratio 7:3. The maximum relevance minimum redundancy (mRMR) was applied to select optimal features from PET, CT, fused images, respectively....
6025 Background: Treatment options for patients (pts) with R/M NPC are limited to palliative chemotherapy. is often associated the Epstein–Barr virus (EBV), a potential antigen immune recognition, and high expression levels of checkpoint receptor programmed death-1 (PD-1) its major ligand PD-L1. Nivolumab disrupts PD-1–mediated signaling, restoring T-cell antitumor function. Methods: In CheckMate 358 (NCT02488759), PD-L1–unselected adults NPC, ECOG PS 0–1, ≤2 prior systemic therapies in...
TPS463 Background: Combination therapy with the anti-HER2 antibody trastuzumab plus fluoropyrimidine and platinum is current standard of care for patients HER2+ mG/GEJc. We hypothesize that combination anti–PD-1 will result in T-cell activation, augment antibody-dependent, cell-mediated cytotoxicity, potentiate antitumor immune response patients. A phase 2 study mG/GEJc demonstrated safety preliminary efficacy trastuzumab/pembrolizumab/chemotherapy; objective rate was 87%, disease control...
To integrate radiomics and dosiomics features from multiple regions in the radiation pneumonia (RP grade ≥ 2) prediction for esophageal cancer (EC) patients underwent radiotherapy (RT).